Terns Pharmaceuticals, Inc.
The company is developing small molecule monotherapy and combination therapies for the treatment of nonalcoholic steatohepatitis and other chronic liver diseases. It is developing candidates such as TERN-101, a therapeutic candidate that demonstrates sustained activation of the farnesoid X receptor in the liver, and TERN-201, a selective inhibitor of vascular adhesion protein-1 (VAP-1). Delaware-based
Overview
Overview | |
|---|---|
Country | United States |
State | California |
Employees | 66 |
Founded | 2017 |
Financials | |
|---|---|
Market Capitalization | 602.14M |
Revenue | |
Operating Income | -103.85M |
Operating Margin | |
Net Income | -91.06M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4811 / 5373 |
Sector : Healthcare | 894 / 1144 |
Industry : Biotechnology | 460 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 2837 / 5565 |
Sector : Healthcare | 404 / 1182 |
Industry : Biotechnology | 183 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4694 / 5436 |
Sector : Healthcare | 872 / 1164 |
Industry : Biotechnology | 447 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4283 / 5330 |
Sector : Healthcare | 735 / 1174 |
Industry : Biotechnology | 320 / 667 |